Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.
|Articles|November 1, 1999
Supplements and Featured Publications
- The Clinical and Economic Impact of Pneumococcal Disease in the Pediatric Population
- Volume 5
- Issue 17 Suppl
Selected Abstracts
Advertisement
Articles in this issue
about 27 years ago
Participating Facultyabout 27 years ago
Introductionabout 27 years ago
Epidemiology of Pneumococcal Diseaseabout 27 years ago
The Costs of Antimicrobial Treatment Failure in Acute Otitis Mediaabout 27 years ago
Prevention of Pneumococcal Disease in High-Risk Pediatric Groupsabout 27 years ago
The Clinical Impact of Pneumococcal Conjugate Vaccinesabout 27 years ago
Economic Impact of Pneumococcal Conjugate Vaccine in Managed Careabout 27 years ago
Into the Era of the Pneumococcal Conjugate Vaccineabout 27 years ago
CME Quizabout 27 years ago
BibliographyAdvertisement
Related to this article
The associate editor of Evidence-Based Oncology says the turnover that will follow this week's midterm election calls for renewed engagement from community oncology leaders with members of Congress, due to pressing reimbursement issues.
Medigap Plan F enrollment has declined since it was closed to new beneficiaries in 2020. The percentage of individual Medigap enrollees relative to non–dually eligible traditional Medicare beneficiaries increased from 2013-2024.
Among the therapeutic alternatives used in Medicare’s drug price negotiations, many were generics or biosimilars, and most differed in mechanistic class from the negotiated drug.
In an insured population with advanced lung cancer, clinical trial participants had lower or similar total health care costs compared with nonparticipants.
Advertisement
Advertisement
Trending on AJMC
1
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
2
How the GOLD 2026 Guidelines Updated COPD Diagnosis and Treatment
3
CF, Bronchiectasis Antimicrobial Resistance Varies Widely by Region
4
COPD Disease Stability Emerges as a Treatment Target in GOLD 2026
5